This search looks for keywords in all of the website’s content. Search tips
Filter by
HumanAdvanced therapiesRegulatory and procedural guidanceResearch and developmentSME
The European Medicines Agency (EMA) plays an important role in ensuring that the needs of older people are taken into account in the development, approval and use of medicines in the European Union. This includes developing guidelines on how to address the specific requirements of older patients in medicine development programmes and improving the...
HumanRegulatory and procedural guidanceMedicinesResearch and development
HumanVeterinaryCompliance and inspectionsRegulatory and procedural guidanceResearch and development
HumanRegulatory and procedural guidancePaediatricsResearch and development
HumanRegulatory and procedural guidanceResearch and development
HumanCompliance and inspectionsRegulatory and procedural guidanceResearch and development
VeterinaryRegulatory and procedural guidanceResearch and developmentScientific guidelines
HumanRegulatory and procedural guidanceRare diseasesResearch and development
VeterinaryRegulatory and procedural guidanceResearch and developmentScientific guidelines
During the 2020-23 COVID-19 public health emergency, the European Medicines Agency (EMA) provided guidance for medicine developers and pharmaceutical companies to help speed up development and approval for COVID-19 medicines and address regulatory challenges arising from the pandemic.
HumanCOVID-19Clinical trialsCompassionate useRegulatory and procedural guidanceMedicine shortagesResearch and developmentScientific advice